BioAsia 2026 Opens in Hyderabad, Spotlighting India’s Expanding Life Sciences Ambitions

The 2026 edition of BioAsia 2026 commenced in Hyderabad on February 17, reaffirming India’s growing stature as a global hub for life sciences, biotechnology and health-tech innovation. The annual summit, one of Asia’s largest biotechnology and healthcare forums, has drawn policymakers, global industry leaders, researchers, start-ups and investors to deliberate on the future of healthcare and biomedical research.

This year’s gathering is expected to host over 4,000 delegates, reflecting expanding international interest in India’s pharmaceutical manufacturing capacity, vaccine leadership and digital health ecosystem. The event provides a platform for strategic partnerships, cross-border collaborations and investment discussions across biotechnology, medical devices, genomics, artificial intelligence in healthcare and drug discovery.

State and industry leaders have positioned the summit as a bridge between research and commercialisation, underscoring Hyderabad’s emergence as a life sciences cluster with strong infrastructure and skilled talent. Panel discussions are set to focus on regulatory innovation, sustainable healthcare models and next-generation therapeutics.

As India seeks to deepen its footprint in global supply chains and health innovation, BioAsia 2026 signals the country’s intent to move beyond manufacturing strength toward becoming a knowledge and research powerhouse.